Vikki A McBain1, John Townend, Noemi Lois. 1. Ophthalmology Department, Grampian University Hospitals-National Health Service Trust, Aberdeen, Scotland, United Kingdom. v.a.mcbain@abdn.ac.uk
Abstract
PURPOSE: To evaluate retinal pigment epithelial (RPE) atrophy in patients with Stargardt disease using autofluorescence imaging (AF). DESIGN: Retrospective observational case series. METHODS: Demographics, best-corrected visual acuity (BCVA), AF images, and electrophysiology responses (group 1, macular dysfunction; group 2, macula + cone dysfunction; group 3, macula + cone-rod dysfunction) were evaluated at presentation and follow-up in a group of 12 patients (24 eyes) with Stargardt disease. The existence, development, and rate of enlargement of areas of RPE atrophy over time were evaluated using AF imaging. A linear regression model was used to investigate the effects of AF and electrophysiology on rate of atrophy enlargement and BCVA, adjusting for age of onset and duration of disease. RESULTS: Eight male and 4 female patients (median age 42 years; range 24-69 years) were followed for a median of 41.5 months (range 13-66 months). All 12 patients had reduced AF compatible with RPE atrophy at presentation and in all patients the atrophy enlarged during follow-up. The mean rate of atrophy enlargement for all patients was 1.58 mm(2)/y (SD 1.25 mm(2)/y; range 0.13-5.27 mm(2)/y). Only the pattern of functional loss present as detected by electrophysiology was statistically significantly associated with the rate of atrophy enlargement when correcting for other variables (P < .001), with patients in group 3 (macula + cone-rod dysfunction) having the fastest rate of atrophy enlargement (1.97 mm(2)/y, SD 0.70 mm(2)/y) (group 1 [macula] 1.09 mm(2)/y, SD 0.53 mm(2)/y; group 2 [macula + cone] 1.89 mm(2)/y, SD 2.27 mm(2)/y). CONCLUSION: Variable rates of atrophy enlargement were observed in patients with Stargardt disease. The pattern of functional loss detected on electrophysiology was strongly associated with the rate of atrophy enlargement over time, thus serving as the best prognostic indicator for patients with this inherited retinal disease.
PURPOSE: To evaluate retinal pigment epithelial (RPE) atrophy in patients with Stargardt disease using autofluorescence imaging (AF). DESIGN: Retrospective observational case series. METHODS: Demographics, best-corrected visual acuity (BCVA), AF images, and electrophysiology responses (group 1, macular dysfunction; group 2, macula + cone dysfunction; group 3, macula + cone-rod dysfunction) were evaluated at presentation and follow-up in a group of 12 patients (24 eyes) with Stargardt disease. The existence, development, and rate of enlargement of areas of RPE atrophy over time were evaluated using AF imaging. A linear regression model was used to investigate the effects of AF and electrophysiology on rate of atrophy enlargement and BCVA, adjusting for age of onset and duration of disease. RESULTS: Eight male and 4 female patients (median age 42 years; range 24-69 years) were followed for a median of 41.5 months (range 13-66 months). All 12 patients had reduced AF compatible with RPE atrophy at presentation and in all patients the atrophy enlarged during follow-up. The mean rate of atrophy enlargement for all patients was 1.58 mm(2)/y (SD 1.25 mm(2)/y; range 0.13-5.27 mm(2)/y). Only the pattern of functional loss present as detected by electrophysiology was statistically significantly associated with the rate of atrophy enlargement when correcting for other variables (P < .001), with patients in group 3 (macula + cone-rod dysfunction) having the fastest rate of atrophy enlargement (1.97 mm(2)/y, SD 0.70 mm(2)/y) (group 1 [macula] 1.09 mm(2)/y, SD 0.53 mm(2)/y; group 2 [macula + cone] 1.89 mm(2)/y, SD 2.27 mm(2)/y). CONCLUSION: Variable rates of atrophy enlargement were observed in patients with Stargardt disease. The pattern of functional loss detected on electrophysiology was strongly associated with the rate of atrophy enlargement over time, thus serving as the best prognostic indicator for patients with this inherited retinal disease.
Authors: Maria Fernanda Abalem; Benjamin Otte; Chris Andrews; Katherine A Joltikov; Kari Branham; Abigail T Fahim; Dana Schlegel; Cynthia X Qian; John R Heckenlively; Thiran Jayasundera Journal: Am J Ophthalmol Date: 2017-10-14 Impact factor: 5.258
Authors: Artur V Cideciyan; Malgorzata Swider; Sharon B Schwartz; Edwin M Stone; Samuel G Jacobson Journal: Invest Ophthalmol Vis Sci Date: 2015-09 Impact factor: 4.799
Authors: Rupert W Strauss; Beatriz Muñoz; Alexander Ho; Anamika Jha; Michel Michaelides; Artur V Cideciyan; Isabelle Audo; David G Birch; Amir H Hariri; Muneeswar G Nittala; SriniVas Sadda; Sheila West; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Rupert W Strauss; Beatriz Muñoz; Alex Ho; Anamika Jha; Michel Michaelides; Saddek Mohand-Said; Artur V Cideciyan; David Birch; Amir H Hariri; Muneeswar G Nittala; SriniVas Sadda; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2017-07-01 Impact factor: 7.389
Authors: Maria Fernanda Abalem; Cynthia X Qian; Kari Branham; Dana Schlegel; Abigail T Fahim; Naheed W Khan; John R Heckenlively; K Thiran Jayasundera Journal: Ophthalmic Genet Date: 2017-07-20 Impact factor: 1.803
Authors: Kaoru Fujinami; Jana Zernant; Ravinder K Chana; Genevieve A Wright; Kazushige Tsunoda; Yoko Ozawa; Kazuo Tsubota; Anthony G Robson; Graham E Holder; Rando Allikmets; Michel Michaelides; Anthony T Moore Journal: Ophthalmology Date: 2014-10-12 Impact factor: 12.079